Chemoradiotherapy in Elderly Patients with Locally Advanced Pancreatic Cancer (70+).

Fudan University

Status: Not yet enrolling

Conditions: Unresectable Locally Advanced Pancreatic Cancer

Study type: Observational

Funder types: Other

Identifiers

NCT06844773

ZSPAC-08

Details and patient eligibility

About

The goal of this observational study is to learn about the therapeutic effects of chemoradiotherapy for older adults (age 70-85) with locally advanced pancreatic cancer. The main question it aims to answer is:

Does chemoradiotherapy represent an effective and safe treatment for older participants without radical surgery? Participants will sequentially receive combined chemotherapy followed by concurrent chemoradiotherapy and subsequent maintenance therapy.

Enrollment: 36 estimated patients

Sex: All

Ages: 70 to 85 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Voluntarily participate and sign the informed consent form
• Age 70-85 years old, life expectancy > 1 year and gender is not limited
• Eastern Cooperative Oncology Group Physical Status Score (ECOG) physical state score<=1 point
• Pathological or cytological confirmation of pancreatic ductal adenocarcinoma (including IPMN malignant transformation, acinar carcinoma, etc., excluding adenosquamous cell carcinoma and neuroendocrine carcinoma)
• The clinical stage is stage III (locally advanced pancreatic cancer), and no radical surgery has been performed (bypass surgery is acceptable), or the patient has resectable pancreatic cancer, but cannot accept surgery or refuse surgery due to physical strength or concomitant diseases
• Have not received any form of anti-tumor therapy before treatment, including systemic chemotherapy, interventional chemotherapy, high-energy focused ultrasound, radiotherapy, immunotherapy, molecular targeted therapy, and anti-tumor traditional Chinese medicine therapy
• No serious hematological, cardiological, pulmonary function abnormalities and autoimmune deficiencies (refer to their respective diagnostic criteria)
• Blood routine index: white blood cell (WBC) >=3.0 × 109/L; Absolute neutrophil count (ANC) >=1.5 × 109/L; Platelets (PLT) >=100 × 109/L; hemoglobin (Hgb) >=90 g/L
• Blood biochemical indexes: AST (SGOT), ALT (SGPT) <=2.5 × upper limit of normal value (ULN); Total bilirubin (TBIL) < = ULN; Serum creatinine (CRE) <=1.5 × ULN
• Coagulation function: prothrombin time (PT), international normalized ratio (INR) <=1.5 × ULN
• Able to comply with the requirements of the study visit plan and other programs.

Exclusion criteria

• Accompanied by malignant tumors of other systems
• Received any form of anti-tumor therapy before treatment, including systemic chemotherapy, interventional chemotherapy, high-energy focused ultrasound, radiotherapy, immunotherapy, molecular targeted therapy, and anti-tumor traditional Chinese medicine therapy
• Have used any other non-anti-tumor research drugs within 4 weeks before treatment
• Combined with uncontrollable hypertension, diabetes, infection, etc.
• Poor compliance, unable or unwilling to sign informed consent
• Patients who are expected to be out of the observation period for 14 days or more during the treatment period.

Trial design

36 participants in 1 patient group

Observation group